透過您的圖書館登入
IP:44.203.58.132
  • 學位論文

眼睛翳狀贅肉中人類乳突病毒感染與p53不活化之研究

HPV infection and p53 inactivation in pterygium

指導教授 : 周明智
若您是本文的作者,可授權文章由華藝線上圖書館中協助推廣。

摘要


研究目的: 最近研究結果指出,患有翳狀贅肉的個案其組織偵測到腫瘤抑制基因p53基因突變,以及p53蛋白異常表現。人類乳突病毒 (Human papillomavirus, HPV) 16與18之病毒株E6蛋白使p53不活化,在子宮頸癌致癌機轉上扮演重要的角色。本研究進一步推論翳狀贅肉致病機轉中,造成p53蛋白不活化可能與人類乳突病毒感染有關。為探究人類乳突病毒16/18病毒株的E6蛋白不活化p53蛋白在翳狀贅肉的發生所扮演的角色,本研究將就病患檢體中人類乳突病毒16或18型的感染情況、人類乳突病毒E6致癌蛋白與p53蛋白表現等彼此之間的相關性做進一步分析。 研究材料與方法: 本研究利用巢疊式聚合脢連鎖反應(nested-PCR)分析自129例罹患翳狀贅肉之翳狀贅肉組織及20例正常無翳狀贅肉的結膜組織檢體中,是否有人類乳突病毒16及18型的感染,並利用直接定序的方式檢測p53基因是否發生突變,此外亦以免疫組織化學染色法偵測p53蛋白與人類乳突病毒E6蛋白。 實驗結果: 129位罹患翳狀贅肉的個案中,31名個案檢體中, 可偵測到人類乳突病毒 16/18 的感染,約佔24% (31 of 129),而正常的20名受測檢體中則無檢出病毒核酸。經由免疫組織化學染色法偵測此31名人類乳突病毒16/18 DNA為陽性的翳狀贅肉的個案檢體中,有15名個案的檢體中可偵測出E6致癌蛋白,約佔48.3% (15 of 31)。另外,在罹患翳狀贅肉的個案中,其p53蛋白表現呈現陰性,與人類乳突病毒16/18 E6致癌蛋白呈現陽性有相關聯,但與p53基因突變的情形無關。 結論: 人類乳突病毒16/18 E6致癌蛋白可在人類乳突病毒 DNA檢測呈現陽性的翳狀贅肉檢體中被偵測出,使p53基因不活化,參與人類乳突病毒感染翳狀贅肉的致病機轉。

並列摘要


Background: Our recent report indicated that tumor suppressor gene ( p53) mutations and protein aberrant expression were detected in pterygium. Inactivation of p53 by Human papillomavirus (HPV) 16/18 E6 plays a crucial role in cervical tumorigenesis. In this study, we further speculate that p53 inactivation may be linked with HPV infection in pterygium pathogenesis. To investigate the involvement of HPV 16/18 E6 in p53 inactivation in pterygium, the association between HPV 16 or HPV 18 infection, the HPV E6 oncoprotein, and p53 protein expression were analyzed in this study. Methods: HPV 16/18 infection was detected by nested-polymerase chain reaction (nested-PCR), the p53 mutation was detected by direct sequencing, and the p53 and the HPV 16/18 E6 proteins were studied using immunohistochemistry on 129 pterygial specimens and 20 normal conjunctivas. Results: The HPV 16/18 were detected in 24% pterygium tissues (31 of 129) but not in the normal conjunctiva, and the HPV 16/18 E6 oncoprotein was detected in 48.3% of HPV 16/18 DNA- positive pterygium tissues (15 of 31). In addition, p53 protein negative expression in pterygium were correlated with HPV 16/18 E6 oncoprotein expression but not with a p53 gene mutation. Conclusions: HPV 16/18 E6 contributes to HPV-mediated pterygium pathogenesis as it is partly involved in p53 inactivation and is expressed in HPV DNA–positive pterygium.

參考文獻


48.Tsai, Y. Y., Cheng, Y. W., Lee, H. et al. (2005). P53 gene mutation spectrum and the relationship between gene mutation and protein expression in pterygium. Mol Vis, 11, 50-55.
2.Cheng, Y. W., Lee, H., Shiau, M. Y., Wu, T. Z., Huang, T. T., & Chang, Y. H. (2008). Human Papillomavirus Type 16/18 Up-regulates the Expression of Interleukin-6 and Anti-apoptotic Mcl-1 in Non-Small Cell Lung Cancer. Clinical Cancer Res, 14(15), 4705-4712.
3.Cheng, Y. W., Wu, T. C., Chen, C. Y., Chou, M. C., Kuo, J. L, & Lee, H. (2008). Human telomerase reverse transcriptase activated by E6 oncoprotein is required for human papillomavirus 16/18-infected lung tumorigenesis. Clinical Cancer Res, 14(22), 7173-7179.
4.Cheng, Y. W., Wu, M. F., Wang, J., Yeh, K. T., Goan, Y. G., Chiou, H. L., Chen, C. Y., & Lee, H. (2007). Human papillomavirus 16/18 E6 oncoprotein is expressed in lung cancer and related with p53 inactivation. Cancer Res, 67(22), 10686-10693.
5.Chowers, I., Pe’er, J., Zamir, E et al. (2001). Proliferative activity and p53 expression in primary and recurrent pterygia. Ophthalmolog,108, 985-988.

延伸閱讀